Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis

被引:46
作者
Govalan, Rajalakshmi [1 ]
Lauzon, Marie [2 ,3 ]
Luu, Michael [2 ,3 ]
Ahn, Joseph C. [4 ]
Kosari, Kambiz [2 ,5 ,6 ]
Todo, Tsuyoshi [2 ,5 ,6 ]
Kim, Irene K. [5 ,6 ]
Noureddin, Mazen [1 ,5 ,7 ]
Kuo, Alexander [1 ,5 ,7 ]
Walid, Ayoub S. [1 ,5 ,7 ]
Sundaram, Vinay [1 ,5 ,7 ]
Lu, Shelly C. [1 ,2 ]
Roberts, Lewis R. [4 ]
Singal, Amit G. [8 ,9 ]
Heimbach, Julie K. [10 ,11 ]
Agopian, Vatche G. [12 ]
Nissen, Nicholas [2 ,5 ,6 ]
Yang, Ju Dong [1 ,2 ,5 ,7 ]
机构
[1] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA
[3] Cedars Sinai Med Ctr, Biostat & Bioinformat Res Ctr, Los Angeles, CA 90048 USA
[4] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA
[5] Cedars Sinai Med Ctr, Comprehens Transplant Ctr, Los Angeles, CA 90048 USA
[6] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA
[7] Cedars Sinai Med Ctr, Karsh Div Gastroenterol & Hepatol, Los Angeles, CA 90048 USA
[8] UT Southwestern Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA
[9] UT Southwestern Med Ctr, Div Digest & Liver Dis, Dallas, TX USA
[10] Mayo Clin, Dept Surg, Rochester, MN USA
[11] Mayo Clin, Liver Transplant Program, Rochester, MN USA
[12] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA
基金
美国国家卫生研究院;
关键词
Hepatocellular carcinoma; Vascular invasion; Surgical resection; Prognosis; MANAGEMENT; PROGNOSIS;
D O I
10.1159/000515554
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Small studies from outside of the USA suggest excellent outcomes after surgical resection for hepatocellular carcinoma (HCC) with vascular invasion. The study aims to (1) compare overall survival after surgical resection and systemic therapy among patients with HCC and vascular invasion and (2) determine factors associated with receipt of surgical resection in a US population. Methods: HCC patients with AJCC clinical TNM stage 7th T3BN0M0 diagnosed between 2010 and 2017 from the National Cancer Database were analyzed. Cox and logistic regression analyses identified factors associated with overall survival and receipt of surgical resection. Results: Of 11,259 patients with T3BN0M0 HCC, 325 (2.9%) and 4,268 (37.9%) received surgical resection and systemic therapy, respectively. In multivariable analysis, surgical resection was associated with improved survival compared to systemic therapy (adjusted hazard ratio: 0.496, 95% confidence interval: 0.426-0.578) with a median survival of 21.4 and 8.1 months, respectively. Superiority of surgical resection was observed in noncirrhotic and cirrhotic subgroups and propensity score matching and inverse probability of treatment weighting adjusted analysis. Asians were more likely to receive surgical resection, whereas Charlson comorbidity >= 3, elevated alpha-fetoprotein, smaller tumor size, care in a community cancer program, and the South or West region were associated with a lower likelihood of surgical resection. Conclusion: HCC patients with vascular invasion may benefit from surgical resection compared to systemic therapies. Demographic and clinical features of HCC patients and region and type of treating facility were associated with surgical resection versus systemic treatment.
引用
收藏
页码:407 / 418
页数:12
相关论文
共 46 条
[1]   Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].
Abou-Alfa, G. K. ;
Meyer, T. ;
Cheng, A. -L. ;
El-Khoueiry, A. B. ;
Rimassa, L. ;
Ryoo, B. -Y. ;
Cicin, I. ;
Merle, P. ;
Chen, Y. H. ;
Park, J. -W. ;
Blanc, J. -F. ;
Bolondi, L. ;
Klumpen, H. -J. ;
Chan, S. L. ;
Zagonel, V. ;
Pressiani, T. ;
Ryu, M. -H. ;
Venook, A. P. ;
Hessel, C. ;
Borgman-Hagey, A. E. ;
Schwab, G. ;
Kelley, R. K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63
[2]  
Allaire M, 2020, JHEP REP, V2, DOI 10.1016/j.jhepr.2020.100134
[3]   A comparison of 12 algorithms for matching on the propensity score [J].
Austin, Peter C. .
STATISTICS IN MEDICINE, 2014, 33 (06) :1057-1069
[4]   A Tutorial and Case Study in Propensity Score Analysis: An Application to Estimating the Effect of In-Hospital Smoking Cessation Counseling on Mortality [J].
Austin, Peter C. .
MULTIVARIATE BEHAVIORAL RESEARCH, 2011, 46 (01) :119-151
[5]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[6]   Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Bruix, Jordi ;
Qin, Shukui ;
Merle, Philippe ;
Granito, Alessandro ;
Huang, Yi-Hsiang ;
Bodoky, Gyrogy ;
Pracht, Marc ;
Yokosuka, Osamu ;
Rosmorduc, Olivier ;
Breder, Valeriy ;
Gerolami, Rene ;
Masi, Gianluca ;
Ross, Paul J. ;
Song, Tianqiang ;
Bronowicki, Jean-Pierre ;
Ollivier-Hourmand, Isabelle ;
Kudo, Masatoshi ;
Cheng, Ann-Lii ;
Llovet, Josep M. ;
Finn, Richard S. ;
LeBerre, Marie-Aude ;
Baumhauer, Annette ;
Meinhardt, Gerold ;
Han, Guohong .
LANCET, 2017, 389 (10064) :56-66
[7]   Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial [J].
Bruix, Jordi ;
Raoul, Jean-Luc ;
Sherman, Morris ;
Mazzaferro, Vincenzo ;
Bolondi, Luigi ;
Craxi, Antonio ;
Galle, Peter R. ;
Santoro, Armando ;
Beaugrand, Michel ;
Sangiovanni, Angelo ;
Porta, Camillo ;
Gerken, Guido ;
Marrero, Jorge A. ;
Nadel, Andrea ;
Shan, Michael ;
Moscovici, Marius ;
Voliotis, Dimitris ;
Llovet, Josep M. .
JOURNAL OF HEPATOLOGY, 2012, 57 (04) :821-829
[8]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[9]   Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].
El-Khoueiry, Anthony B. ;
Sangro, Bruno ;
Yau, Thomas ;
Crocenzi, Todd S. ;
Kudo, Masatoshi ;
Hsu, Chiun ;
Kim, Tae-You ;
Choo, Su-Pin ;
Trojan, Jorg ;
Welling, Theodore H., III ;
Meyer, Tim ;
Kang, Yoon-Koo ;
Yeo, Winnie ;
Chopra, Akhil ;
Anderson, Jeffrey ;
dela Cruz, Christine ;
Lang, Lixin ;
Neely, Jaclyn ;
Tang, Hao ;
Dastani, Homa B. ;
Melero, Ignacio .
LANCET, 2017, 389 (10088) :2492-2502
[10]   Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J].
Finn, Richard S. ;
Qin, Shukui ;
Ikeda, Masafumi ;
Galle, Peter R. ;
Ducreux, Michel ;
Kim, Tae-You ;
Kudo, Masatoshi ;
Breder, Valeriy ;
Merle, Philippe ;
Kaseb, Ahmed O. ;
Li, Daneng ;
Verret, Wendy ;
Xu, Derek-Zhen ;
Hernandez, Sairy ;
Liu, Juan ;
Huang, Chen ;
Mulla, Sohail ;
Wang, Yulei ;
Lim, Ho Yeong ;
Zhu, Andrew X. ;
Cheng, Ann-Lii .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1894-1905